https://orcid.org/0000-0001-8299-3146
References
- Ninlaro | European Medicines Agency. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/ninlaro
- Haute Autorité de Santé - NINLARO (ixazomib), antinéoplasique. Available from: https://www.has-sante.fr/portail/jcms/c_2779830/fr/ninlaro-ixazomib-antineoplasique
- National Institute for Health and Care Excellence (NICE), Topic selection | Our programmes | What we do | About. Available from: https://www.nice.org.uk/about/what-we-do/our-programmes/topic-selection
- Haute Autorité de Santé - Commission de la transparence. Available from: https://www.has-sante.fr/portail/jcms/c_412210/fr/commission-de-la-transparence
- National institute for health and care excellence: overview of technology appraisals for patient and carer organisations, Public Involvement Programme. April 2014. Available from: https://www.nice.org.uk/Media/Default/About/NICE-Communities/Public-involvement/Developing-NICE-guidance/Overview-of-technology-appraisals-patient-carer-groups.pdf
- McCabe C, Claxton K, Culyer AJ. The NICE cost-effectiveness threshold: what it is and what that means. Pharmacoeconomics. 2008;26:733–6.
- National Institute for Health and Care Excellence (NICE), Patient access schemes, commercial access agreements and flexible pricing | Guide to the processes of technology appraisal | Guidance | NICE. Available from: https://www.nice.org.uk/process/pmg19/chapter/patient-access-schemes-commercial-access-agreements-and-flexible-pricing
- Haute Autorité de Santé - Le service médical rendu (SMR) et l’amélioration du service médical rendu (ASMR). Available from: https://www.has-sante.fr/portail/jcms/r_1506267/fr/le-service-medical-rendu-smr-et-l-amelioration-du-service-medical-rendu-asmr
- Giorgi D. [The French medecine pricing committee]. Ann Pharm Fr. 2017;75:373–384.
- Toumi M, Motrunich A, Millier A, et al. Analysis of health economics assessment reports for pharmaceuticals in France - understanding the underlying philosophy of CEESP assessment. J Mark Access Health Policy. 2017;5:1344088.
- Haute Autorité de Santé: L’évaluation médico-économique des Médicaments et Dispositifs Médicaux. Dossier de presse: Conférence de presse; 2014 décembre 18.
- National Institute for Health and Care Excellence (NICE), Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma | Guidance and guidelines | NICE. Available from: https://www.nice.org.uk/guidance/ta505
- Moreau P, Masszi T, Grzasko N, et al. TOURMALINE-MM1 study group: oral Ixazomib, Lenalidomide, and Dexamethasone for multiple Myeloma. N Engl J Med. 2016;374:1621–1634.
- Direction Générale de l'Offre de Soins (DGOS): Le forfait innovation. Available from: https://solidarites-sante.gouv.fr/systeme-de-sante-et-medico-social/recherche-et-innovation/forfait-innovation
- Agence Nationale de Sécurité du Médicament et des produits de santé à la référence, Qu’est ce qu’une autorisation temporaire d’utilisation? - ANSM: Agence nationale de sécurité du médicament et des produits de santé. Available from: https://www.ansm.sante.fr/Activites/Autorisations-temporaires-d-utilisation-ATU/Qu-est-ce-qu-une-autorisation-temporaire-d-utilisation/(offset)/0
- Haute Autorité de Santé, NINLARO 17052017 CT15988 TRANSCRIPTION. Available from: https://www.has-sante.fr/portail/plugins/ModuleXitiKLEE/types/FileDocument/doXiti.jsp?id=c_2803717
- National Institute for Health and Care Excellence (NICE), Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma | Final Scope | NICE. Available from: https://www.nice.org.uk/guidance/ta505/history
- Armoiry X, Connock M, Tsertsvadze A, et al. Ixazomib for relapsed or refractory multiple Myeloma: review from an evidence review group on a NICE single technology appraisal. Pharmacoeconomics. 2018;36:1073–1081.
- Dillon A, Landells LJ. NICE, the NHS, and cancer drugs. JAMA. 2018;319:767–768.
- Haute Autorité de Santé,COMPTE RENDU CT 17052017. Available from: https://www.has-sante.fr/portail/plugins/ModuleXitiKLEE/types/FileDocument/doXiti.jsp?id=c_2775511
- Avis relatif aux prix de spécialités pharmaceutiques, JORF n°0252 du 31 octobre 2018 texte n° 142, https://www.legifrance.gouv.fr/affichTexte.do?cidTexte=JORFTEXT000037543195&categorieLien=id.
- Haute Autorité de Santé - La commission de la transparence précise et adapte ses principes d’évaluation des médicaments. Available from: https://www.has-sante.fr/portail/jcms/c_2877573/fr/la-commission-de-la-transparence-precise-et-adapte-ses-principes-d-evaluation-des-medicaments